ESR1 peptides vaccine study - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find out if a new vaccine (ESR1 peptides) is safe and if they will help people with Estrogen receptor positive (ER+) breast cancer.

What is the Condition Being Studied?

Breast Cancer

Who Can Participate in the Study?

-Adults who:
--Are diagnosed with breast cancer
--Have completed chemotherapy or surgery.

Age Group
Adults

What is Involved?

If you choose to join this study you will:
-Get the study vaccine (ESR1 peptide)
-Return to the Duke Cancer Center for follow-up visits 6-8 times over 10 weeks.
-Be contacted by phone every 12 weeks to see how you are doing
-Have a skin biopsy (piece of skin will be taken) where the study vaccine was injected.

Study Details

Full Title
A Phase I Study of Cancer Peptides plus GM-CSF and Adjuvant Following Completion of Prescribed Systemic Therapy of Estrogen Receptor Positive Breast Cancer
Principal Investigator
H. KimLyerly
Protocol Number
IRB: PRO00104868
NCT: NCT04270149
Phase
Phase I
ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Participate
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698